NIH Devotes $9.2M to Next-Gen Sequencing under Pharmacogenomics Research Network Expansion

The PGRN, which is spearheaded by the National Institute of General Medical Sciences and funded by nine NIH components, was launched in 2000 and has already identified gene variants linked to drug responses for different cancers, heart disease, asthma, nicotine addition, and other conditions. The expanded network will continue this research and move into new areas, including rheumatoid arthritis and bipolar disorder.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.